Lv4
482 积分 2021-02-07 加入
9MW2821, a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open label, multicenter, phase Ⅰ/Ⅱ study
3天前
待确认
YIA25-001: Molecular Residual Disease (MRD) Guided Adjuvant Therapy In Renal Cell Carcinoma (RCC) - The MRD GATE RCC Study
3天前
求助中
Development of a 90-Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection
4天前
已完结
Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer
4天前
已完结
Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial
4天前
已完结
YIA25-001: Molecular Residual Disease (MRD) Guided Adjuvant Therapy In Renal Cell Carcinoma (RCC) - The MRD GATE RCC Study
6天前
已关闭
Homologous recombination repair gene alteration is strongly associated with more prostate-specific membrane antigen-positive metastases in newly diagnosed hormone-sensitive prostate cancer with ≤5 conventional imaging defined distant metastases
7天前
已完结
Circulating tumour DNA and circulating tumour cells in bladder cancer — from discovery to clinical implementation
9天前
已完结
Current and future directions in theranostics for neuroendocrine prostate cancer
12天前
已完结
A shifting market environment and strategies fueling innovation in prostate cancer treatment
16天前
已完结
皖公网安备34019202002308
